664 related articles for article (PubMed ID: 15208518)
1. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
2. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
5. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
[TBL] [Abstract][Full Text] [Related]
6. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Miller EA; Leslie DL; Rosenheck RA
J Nerv Ment Dis; 2005 Jun; 193(6):387-95. PubMed ID: 15920379
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Cohen D
Pharmacopsychiatry; 2004 Jan; 37(1):1-11. PubMed ID: 14750042
[TBL] [Abstract][Full Text] [Related]
8. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
10. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
[TBL] [Abstract][Full Text] [Related]
11. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
12. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
13. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
14. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
15. Tardive dyskinesia rates with atypical antipsychotics in older adults.
Jeste DV
J Clin Psychiatry; 2004; 65 Suppl 9():21-4. PubMed ID: 15189108
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety of antipsychotics: another look at the risk of diabetes.
Moisan J; Turgeon M; Desjardins O; Grégoire JP
Can J Psychiatry; 2013 Apr; 58(4):218-24. PubMed ID: 23547645
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
18. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
Gianfrancesco F; Pesa J; Wang RH
J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
[TBL] [Abstract][Full Text] [Related]
20. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Mosolov SN; Kabanov SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
